An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...

Homomorphic encryption is a method of performing calculations on encrypted information without decrypting it first. Why do you care about some arcane computer math? Because it could make cloud ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) said the FDA has declined to approve its drug Zynquista, also known as sotagliflozin, as an adjunct to insulin therapy for glycemic control in adults with type 1 ...

Lexicon Pharmaceuticals currently offers three late-stage assets - Zynquista, Inpefa, and pilavapadin - each with high-reward potential but significant regulatory and commercial risks. Zynquista's ...

30 years ago, Lexicon was the name in reverb. Their advanced algorithms were the envy of all, and the boxes that produced them were pricey, overdesigned affairs aimed at pro studios. However, by the ...

THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it has entered into a securities purchase agreement (the “purchase ...

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

Lexicon Pharmaceuticals announced that it received a complete response letter (CRL) from the FDA regarding its New Drug Application for Zynquista™ (sotagliflozin), which was proposed as an adjunct to ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for obesity and related metabolic disorders.